PegBio Co., Ltd.
🇭🇰Hong Kong, China
- Country
- 🇭🇰Hong Kong, China
- Ownership
- Holding
- Established
- 2008-05-13
- Employees
- 51
- Market Cap
- -
- Website
- http://www.pegbio.com
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- PegBio Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06350812
- Locations
- 🇨🇳
The Third XIANGYA Hospital of Central South University, Changsha, Hunan, China
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-718 Injection in Chinese Obese Subjects.
- First Posted Date
- 2023-11-27
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- PegBio Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT06147544
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal Function
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- PegBio Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05328843
- Locations
- 🇨🇳
Jia Miao, Chengdu, Sichuan, China
Study to Evaluate the Efficacy and Safety of PB-201 in Type 2 Diabetic Mellitus Patients With Poor Glycemic Control Via Metformin Hydrochloride Monotherapy
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2022-04-22
- Lead Sponsor
- PegBio Co., Ltd.
- Target Recruit Count
- 546
- Registration Number
- NCT05326490
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- PegBio Co., Ltd.
- Target Recruit Count
- 672
- Registration Number
- NCT05102149
- Locations
- 🇨🇳
Shiyan Renmin Hospital, Shiyan, Hubei, China
🇨🇳Lu'an People's Hospital, Lu'an, Anhui, China
🇨🇳Lanzhou University Second Hospital, Lanzhou, Gansu, China
A Phase 1, Double-blind, Randomized, Placebo-controlled, Single- and Multiple-dose Escalating Study
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- PegBio Co., Ltd.
- Target Recruit Count
- 82
- Registration Number
- NCT05021666
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Daytona Beach, Florida, United States
Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- PegBio Co., Ltd.
- Target Recruit Count
- 620
- Registration Number
- NCT04504396
- Locations
- 🇨🇳
Beijing University People's Hospital, Beijing, Beijing, China
Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- PegBio Co., Ltd.
- Target Recruit Count
- 273
- Registration Number
- NCT04504370
- Locations
- 🇨🇳
Central South University The Second Xiangya Hospital, Changsha, Hunan, China
Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- PegBio Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT03973515
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- PegBio Co., Ltd.
- Target Recruit Count
- 214
- Registration Number
- NCT03604419
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
© Copyright 2024. All Rights Reserved by MedPath